Place of anti-histamine in therapy of itching skin of children
ALLERGOLOGY AND IMMUNOLOGY IN PEDIATRICS | REVIEW
Volume 66 • Issue 3 • September 2021, pp. 4-16
Received: 08.09.2021 | Publication date: 30.09.2021
S.S. Masalskiy1,3, Yu.S. Smolkin1,2,3
1 Association Pediatric Allergist and Immunologist Russia, Moscow, Russia;
2 Academy postgraduate education «Federal State Budget Founding Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological Agency», Moscow, Russia;
3 «Scientific-Clinical Consultative Center of Allergology and Immunology», Ltd, Moscow, Russia
Abstract
Itching is a frequent condition at a doctor’s appointment of any speciality. A quarter of patients complain of itching of various etiology. In real practice, H1-histamine receptor blockers are prescribed for itching in the first place. The article considers a complex of diseases accompanied by itching of the skin. The itching is a reflex. The classification contains a lot of forms:local and systemic; prurigogenic, neuropathic and psychogenic. Itching has no stable pathogenesis and can be provoked by various conditions. The main types of sensory neurons are opiate and 5-HT-receptors. Urticaria and food allergy are associated with irritation of the skin receptors with histamine and other mast cell mediators. In these cases, antihistamines are the drug of choice regardless of the aetiology of urticaria. In atopic dermatitis, the itching has a complex aetiology: transepidermal water loss, chronic inflammation of the skin with the participation of many cells, secondary hyperinervation of the skin with the formation of a pathological activity focus in the brain. This requires a comprehensive approach to therapy. Xerosisis overcome by the use of emollients and rational skincare. The presence of exacerbation makes it necessary to prescribe topical steroids or calcineurin inhibitors for an acute period s. In the case of the addition of psychogenic itching, antiserotonin 5-HT-blockers drugs, hydroxyzine can be considered. H1-receptor blockers do not affect the intensity of skin lesions in dermatitis, but some molecules can reduce the itching. Quifenadine is the antihistamine dug of the second generation. It can be used in the treatment of allergic itching dermatoses. The rapid onset of action allows you to reach the maximum concentration in the tissues within 1 hour, activate monooxidase and neutralise histamine in the tissue. Quifenadine absence a sedative effect and no respiratory depression.Instructions for the use of the medicinal product can increase the dose by 1,5–2 times.It makes the drug useful for the treatment of manifestations of food allergies and urticaria. The dual antihistamine and antiserotonin action allow the successful use of quifenadine in the acute period of atopic dermatitis, especially provoked by contact with an allergen.
References
1. Weisshaar E. Epidemiology of Itch. Curr Probl Dermatol. 2016;50:5-10. doi:10.1159/000446010
2. Dong X, Dong X. Peripheral and Central Mechanisms of Itch. Neuron. 2018;98(3):482-494. doi:10.1016/j.neuron.2018.03.023
3. Murashkin NN et al. Pruritus and Atopic Dermatitis: from Etiological Features to Management. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020; 19 (6): 468–476. doi: 10.15690/vsp.v19i6.2151 (In Rus)
4. Чебуркин АА. Зуд: дифференциальная диагностика и терапия. Терапевтический архив. 2014;86(4):85-90. [Cheburkin AA. Itching: Differential diagnosis and therapy. Therapeutic archive. 2014;86(4):85-90] (In Rus)
5. Rajagopalan M, Saraswat A, Godse K, et al. Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review. Indian J Dermatol. 2017;62(1):7-17. doi:10.4103/0019-5154.198036
6. Волков ММ, Добронравов МА. Уремический зуд у больных на заместительной почечной терапии. Нефрология. 2006;10(2):110-117. [Volkov MM, Dobronravov MA. Uremicheskii zud u bol’nykh na zamestitel’noi pochechnoi terapii. Nefrologiya. 2006;10(2):110-117]
7. Pruritus: Overview of management. Official reprint from UpToDate 15 jan 2019 Authors: Sara B Fazio, MD, Gil Yosipovitch, MD
8. Smolkin YS, et al. Consensus document APAIR: atopic dermatitis in children — update 2019 (short version) part 2. Allergology and Immunology in Pediatrics. 2020;61(2):4-26. (In Russ.) https://doi.org/10.24411/2500-1175-2020-10004
9. Тамразова ОБ. Зуд у детей. Аллергология и иммунология в педиатрии. 2014; 39 (4): 27-37. Tamrazova OB. Zud u detei. Allergologiya i immunologiya v pediatrii. 2014; 39 (4): 27-37]
10. VanZuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen APM, Arents BWM. Emollients and moisturisers for eczema (Review). Cochrane Database of Systematic Reviews. 2019;CD012119(2):426. doi:10.1002/14651858.CD012119.pub2.www.cochranelibrary.com
11. Sakai et al., Low-Threshold Mechanosensitive VGLUT3-Lineage Sensory Neurons Mediate Spinal Inhibition of Itch by Touch JNeurosci 2020 DOI: https://doi.org/10.1523/JNEUROSCI.0091-20.2020
12. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. Journal of the European Academy of Dermatology and Venereology. 2018;32(6):850-878. doi:10.1111/jdv.14888
13. Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. British Journal of Pharmacology. 2020;177: 469-489. doi:10.1111/bph.14524
14. Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD012167. DOI: 10.1002/14651858.CD012167.pub2. Accessed 13 August 2021.
15. El Hachem M, Di Mauro G, Rotunno R, et al. Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach – summary document from an Italian expert group. Ital J Pediatr. 2020;46:11. doi:10.1186/s13052-020-0777-9
16. Kittaka H, Tominaga M. The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin. Allergology International. 2017;66(1):22-30. doi:10.1016/J.ALIT.2016.10.003
17. Ильченко СИ, Науменко НВ, Пинаева НЛ. Сравнительная оценка эффективности применения препарата Фенкарол при атопическом дерматите у детей дошкольного возраста. Клиническая иммунология. Аллергология. Инфектология. 2014; 9-10 (78-79): 51- 54 [Il’chenko SI, Naumenko NV, Pinaeva NL. Sravnitel’naya otsenka ehffektivnosti primeneniya preparata Fenkarol pri atopicheskom dermatite u detei doshkol’nogo vozrasta. Klinicheskaya immunologiya. Allergologiya. Infektologiya. 2014; 9-10 (78-79): 51- 54]
18. Зайков СА, Стремедловский БА, Эффективность Фенкарола в лечении обострений хронической крапивницы. Клиническая иммунология. Аллергология. Инфектология. 2014; 2: 48-54 [Zaikov SA, Stremedlovskii BA, Ehffektivnost’ Fenkarola v lechenii obostrenii khronicheskoi krapivnitsy. Klinicheskaya immunologiya. Allergologiya. Infektologiya. 2014; 2: 48-54]
19. Куценко ИВ, Свистунов ИВ, Милус ИЕ. Противозудная терапия больных псориазом. Український журнал дерматології, венерології, косметології.2013; 2: 123-126. [Kutsenko IV, Svistunov IV, Milus IE. Protivozudnaya terapiya bol’nykh psoriazom. Ukraїns’kii zhurnal dermatologії, venerologії, kosmetologії.2013; 2: 123-126.]
Citation
Masalskiy SS, Smolkin YuS. Place of anti-histamine in therapy of itching skin of children. Allergology and Immunology in Pediatrics. 2021;3(66):4–16. (In Russ.) https://doi.org/10.53529/2500-1175-2021-3-4-16
For correspondence:
Sergey S. Masalskiy
Candidate of Science, APAIR Secretary, Physician
0000-0002-2048-5709
6, Ostrovitianova, 117513, Moscow, Russia
masalsky@live.com
Supporting agencies:
company «Olainfarm»
This work is licensed under a Creative Commons Attribution- ShareAlike 4.0 International License